Opinion|Videos|July 30, 2024
Examining Key Data from DAREON-8
Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- DAREON-8: Phase 1 Clinical Trial of Combination Therapy with BI 764532, a DLL3 Targeting T-Cell Engager
- Please share your opinions of the therapeutic potential of Bl 764532, an lgG-like T-cell engager, for its ability to induce selective T-cell mediated tumor cell lysis when added to SOC (carboplatin + etoposide + atezolizumab) for previously untreated patients with ES-SCLC:
- Is a commercial molecular assay currently available to identify the presence of the delta-like ligand 3 notch receptor in patients with SCLC?
- Are you encouraged by an overall response rate of 28% and a 54% disease control rate in the Phase I trial?
- For which line of therapy do you envision BI 764532, if approved?
- Based on the exclusion criteria for the dose escalation trial, are you concerned that this agent may be associated with cardiovascular, cerebrovascular, and/or immunosuppressive TRAEs?
Advertisement
Related to this article
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
4
For Early Prostate Cancer ‘Active Surveillance’ Is Now #1 Choice
5